Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066458 | 0.75 | CSNK2A2 (0.44) | KDM4E | |
| SCHEMBL1180188 | 0.73 | NPC1 (0.47) | CYP3A4IDO1HPGDLMNASMN1; SMN2 | |
| SCHEMBL2391062 | 0.70 | CYP3A4 (0.41) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL7738496 | 0.69 | HPGD (0.39) | CYP3A4HPGDLMNASMN1; SMN2TNKS | |
| SCHEMBL18148991 | 0.67 | CYP11B1 (0.50) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4506826 | 0.66 | MAPK10 (0.54) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4512339 | 0.66 | KDM4E (0.42) | CYP3A4IDO1HPGDADRA2AADRA2B | |
| SCHEMBL4509516 | 0.66 | RAD52 (0.48) | CYP3A4IDO1HPGDLMNASMN1; SMN2 | |
| SCHEMBL4504196 | 0.66 | CDK4 (0.41) | CYP3A4IDO1HPGDLMNASMN1; SMN2 | |
| SCHEMBL24067296 | 0.66 | KDR (0.59) | HPGDLMNASMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | UMOJA BIOPHARMA, INC. (US) | 2026-01-29 | — | — | US | claimed |
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | Umoja Bioharma, Inc. (US) | 2025-12-04 | — | — | US | claimed |
| US-20250354118-A1 | COMPOSITIONS AND METHODS FOR NK CELL DIFFERENTIATION | UMOJA BIOPHARMA, INC. (US) | 2025-11-20 | — | — | US | claimed |
| EP-4562133-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | Umoja Biopharma, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4536693-A1 | ENGINEERED STEM CELLS AND USES THEREOF | Umoja Biopharma, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4536811-A2 | COMPOSITIONS AND METHODS FOR NK CELL DIFFERENTIATION | Umoja Biopharma, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4381048-A1 | METHODS OF T CELL PRODUCTION | Adaptimmune Limited (GB) | 2024-06-12 | — | — | EP | claimed |
| WO-2024026391-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | UMOJA BIOPHARMA, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2023240282-A1 | ENGINEERED STEM CELLS AND USES THEREOF | UMOJA BIOPHARMA, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023240248-A2 | COMPOSITIONS AND METHODS FOR NK CELL DIFFERENTIATION | UMOJA BIOPHARMA, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2017066530-A1 | NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF | ANTHROGENSIS CORPORATION (US) | 2017-04-20 | — | — | WO | claimed |
| WO-2016191879-A1 | METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF | Héma-Québec (CA) | 2016-12-08 | — | — | WO | claimed |
| WO-2016109661-A1 | NATURAL KILLER CELLS AND USES THEREOF | ANTHROGENESIS CORPORATION (US) | 2016-07-07 | — | — | WO | claimed |
| EP-1442039-A1 | PYRIMIDO (4,5-B) INDOLE DERIVATIVES | Bayer HealthCare AG (DE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037898-A1 | PYRIMIDO [4,5-B] INDOLE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-05-08 | — | — | WO | claimed |
| EP-0964865-B1 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | UPJOHN CO (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0964865-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998042708-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1998-10-01 | — | — | WO | claimed |
| EP-0812322-A1 | PYRIMIDO 4,5-b]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-17 | — | — | EP | claimed |
| WO-1996026941-A1 | PYRIMIDO[4,5-b]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367290-A1 | ENGINEERED STEM CELLS AND USES THEREOF | IL2RA, IL2, IL15RA | CYP3A4 4425/4885IDO1 2248/4885HPGD 1948/4885 |
| US-20260028588-A1 | DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE | BMP4, FLT4, FGF2 | CYP3A4 2987/4885IDO1 1537/4885HPGD 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.